Very exciting news for advanced Parkinson's disease patients. With all the caveats associated with a 12-patient open-label study, the...

"The threat of the Inflation Reduction Act is so severe that Merck has fielded questions about whether it would choose to delay the...

Pretty exciting news for the neurodegeneration field for a PROTAC leader like Arvinas to jump in, providing another modality tool. For a...

Am I totally crazy to think this way? Wegovy cut the risk of major cardiovascular adverse events by 20% after 5 years and it's annual...

The Ph2 failure of Galecto's GB0139 is a salient reminder that IPF remains a grave yard for clinical trials while patients continue to...

Interesting approach to trying to avoid ARIA issues faced by #leqembi and #donanemab, at least hypothetically. I'm curious about a few...

Lilly's donanemab Ph3 TRAILBLAZER ALZ-2 full results are out. A few really interesting observations from my perspective: 1. By 76 weeks,...

Safety issues and high price of the current anti-amyloid drugs definitely prevent them from being used before Alzheimer's symptoms...

This kind of blood-based test will be a big deal for accelerating the adoption of newly approved Alzheimer's drugs. This reminds me of an...

Geat news for Alzheimer's disease patients and a satisfying outcome for Eisai and Biogen, which have been very resilient in the fight...

Disappointing results for psoriasis patients waiting for a pill that's as effective as second generation biologics like anti-IL-17 and...

A very candid article about the limitations of AI in drug discovery. If all the #drugdiscovery companies can be more candid about what...

#immunology is red-hot now with another major acquistion following Merck's Prometheus acquisition. In the case of Dice, the thesis is...

Interesting finding by Truveta. A 125% increase of APOE4 status testing rate during 09/22-01/23 period vs. 09/21-01/22, possibly due to...

AI is a tool you can use to accelerate drug discovery and development in some aspects. Don't expect to blow potential pharma partners and...

A great session on target selection at BIO "Perspectives on Target Selection: How Companies Approach a Critical Decision", including...

It was wonderful to listen to an all-female panel on how to turn platform technologies into life-changing therapeutics. My key takeaways...

Smart move, but could've been done earlier. It highlights two things: 1. There's always a tendency to keep a program alive for too long,...

#Target2Drug bioAdvisory has been in business for 4 months and I've won 4 clients. I'm extremely proud of the fact that 3 out of my 4...

Did EQRx underestimate all the hurdles to disrupt the US drug pricing from the get-go? Or its ambition was really crushed by unexpected...